• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亲子对中未检测到致病变异的法布里病病例。

Cases of Fabry Disease in Which Pathogenic Variants Are Not Detected in Parent-Child Pairs.

作者信息

Akeho Naoki, Muta Kumiko, Torigoe Kenta, Kitamura Mineaki, Sawada Takaaki, Nakamura Kimitoshi, Mukae Hiroshi, Nishino Tomoya

机构信息

Department of Nephrology, Izumikawa Hospital, Minamishimabara, JPN.

Department of Nephrology, Nagasaki University Hospital, Nagasaki, JPN.

出版信息

Cureus. 2024 Jul 9;16(7):e64127. doi: 10.7759/cureus.64127. eCollection 2024 Jul.

DOI:10.7759/cureus.64127
PMID:39119442
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11307133/
Abstract

A 15-year-old male has been experiencing fever, limb pain during exercise, and reduced sweating since childhood. During an investigation into his fever, a family history of Fabry disease was discovered, prompting a referral to our department. He was diagnosed with Fabry disease based on decreased alpha-galactosidase A (α-Gal A) activity. Concurrently, his mother was found to have experienced limb pain during fevers since childhood, and she was also diagnosed with Fabry disease based on decreased α-Gal A activity. In the genetic analysis of both individuals, the IVS1+17A>G GLA variant was identified. This variant is considered benign and not classified as a pathogenic variant. Enzyme replacement therapy has been effective in improving clinical symptoms. His sister, who has not been diagnosed with Fabry disease due to normal clinical symptoms and α-GAL A activity, also had the same variant. Among the various GLA variants, many are classified as benign rather than pathogenic. In the present cases, the possibility of other factors that cannot be identified by genetic analysis is suggested, making this case significant and worth reporting.

摘要

一名15岁男性自幼出现发热、运动时肢体疼痛及出汗减少症状。在对其发热情况进行调查时,发现有法布里病家族史,遂转诊至我科。根据α - 半乳糖苷酶A(α - Gal A)活性降低,他被诊断为法布里病。同时,发现其母亲自幼发热时也有肢体疼痛症状,基于α - Gal A活性降低,她也被诊断为法布里病。在对两人的基因分析中,鉴定出IVS1 + 17A>G GLA变异。该变异被认为是良性的,未被归类为致病变异。酶替代疗法已有效改善临床症状。他的姐姐因临床症状和α - GAL A活性正常未被诊断为法布里病,但也有相同变异。在各种GLA变异中,许多被归类为良性而非致病性。在本病例中,提示存在基因分析无法识别的其他因素的可能性,使得该病例具有重要意义且值得报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/4f7de51422fa/cureus-0016-00000064127-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/613fd48c5ab1/cureus-0016-00000064127-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/321cc056a43f/cureus-0016-00000064127-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/4f7de51422fa/cureus-0016-00000064127-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/613fd48c5ab1/cureus-0016-00000064127-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/321cc056a43f/cureus-0016-00000064127-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84b7/11307133/4f7de51422fa/cureus-0016-00000064127-i03.jpg

相似文献

1
Cases of Fabry Disease in Which Pathogenic Variants Are Not Detected in Parent-Child Pairs.亲子对中未检测到致病变异的法布里病病例。
Cureus. 2024 Jul 9;16(7):e64127. doi: 10.7759/cureus.64127. eCollection 2024 Jul.
2
A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.男性和女性法布里病诊断的综合检测算法。
Mol Genet Metab. 2020 Jul;130(3):209-214. doi: 10.1016/j.ymgme.2020.04.006. Epub 2020 May 3.
3
Late-onset and classic phenotypes of Fabry disease in males with the -Thr410Ala mutation.男性 Fabry 病迟发性和经典表型与 -Thr410Ala 突变。
Open Heart. 2023 Mar;10(1). doi: 10.1136/openhrt-2023-002251.
4
Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.血浆溶菌酶糖脂酰基鞘氨醇作为生物标志物用于从多学科诊所选择进行基因分析的法布雷病高危患者的有效性。
Genet Med. 2019 Jan;21(1):44-52. doi: 10.1038/gim.2018.31. Epub 2018 Mar 15.
5
Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.在一项针对年轻卒中患者的大型法布里病筛查项目中鉴定出的α-半乳糖苷酶A基因突变的表型特征。
Clin Neurol Neurosurg. 2013 Jul;115(7):1088-93. doi: 10.1016/j.clineuro.2012.11.003. Epub 2012 Dec 4.
6
[Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].[一个家系中由GLA基因变异引起的法布里病的基因型-表型分析]
Zhonghua Er Ke Za Zhi. 2024 Mar 25;62(4):345-350. doi: 10.3760/cma.j.cn112140-20231007-00258.
7
Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant.溶血型Gb3升高表明R118C GLA突变是一种病理性法布里变异体。
JIMD Rep. 2019;45:95-98. doi: 10.1007/8904_2018_146. Epub 2018 Dec 20.
8
[Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].[摩德纳市接受肾脏替代治疗患者的法布里病筛查试验]
G Ital Nefrol. 2018 Mar;35(2).
9
Case report: mutation of a-galactosidase A in a female patient with end-stage renal disease: report of a case of late diagnosis of Anderson-Fabry disease.病例报告:一名终末期肾病女性患者α-半乳糖苷酶A突变:安德森-法布里病晚期诊断病例报告
Front Genet. 2023 Sep 14;14:1122893. doi: 10.3389/fgene.2023.1122893. eCollection 2023.
10
Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing.干血斑法提高法布雷病诊断准确率:酶活性、溶酶体神经酰胺三己糖苷蓄积和 GLA 基因突变分析。
Clin Genet. 2021 Jun;99(6):761-771. doi: 10.1111/cge.13936. Epub 2021 Feb 10.

本文引用的文献

1
Novel enhancer mediates the readthrough loci and gene expressions associated with fabry disease.新型增强子介导与法布里病相关的通读位点和基因表达。
Front Genet. 2023 Dec 13;14:1229088. doi: 10.3389/fgene.2023.1229088. eCollection 2023.
2
Newborn Screening for Fabry Disease: Current Status of Knowledge.法布里病的新生儿筛查:知识现状
Int J Neonatal Screen. 2023 Jun 5;9(2):31. doi: 10.3390/ijns9020031.
3
Fabry Disease: The Current Treatment Landscape.法布里病:当前的治疗现状。
Drugs. 2021 Apr;81(6):635-645. doi: 10.1007/s40265-021-01486-1. Epub 2021 Mar 15.
4
DNA methylation impact on Fabry disease.DNA 甲基化对法布里病的影响。
Clin Epigenetics. 2021 Feb 2;13(1):24. doi: 10.1186/s13148-021-01019-3.
5
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.Lyso-Gb3 与 Fabry 病患者的不良长期预后相关。
J Med Genet. 2022 Mar;59(3):287-293. doi: 10.1136/jmedgenet-2020-107338. Epub 2021 Jan 25.
6
Fabry disease revisited: Management and treatment recommendations for adult patients.重新审视法布里病:成年患者的管理和治疗建议。
Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28.
7
The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.α-半乳糖苷酶A p.Arg118Cys变异体不会导致法布里病表型:来自个体患者和家系研究的数据。
Mol Genet Metab. 2015 Feb;114(2):248-58. doi: 10.1016/j.ymgme.2014.11.004. Epub 2014 Nov 9.
8
A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance.法布里病筛查的系统评价:意义未明的基因变异个体的患病率
J Med Genet. 2014 Jan;51(1):1-9. doi: 10.1136/jmedgenet-2013-101857. Epub 2013 Aug 6.
9
Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease.溶血神经酰胺三己糖苷表明α-半乳糖苷酶A突变D313Y在法布里病中与临床无关。
JIMD Rep. 2013;7:99-102. doi: 10.1007/8904_2012_154. Epub 2012 Jul 1.
10
Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).台湾地区对法布里病进行的新生儿筛查显示,迟发型GLA突变c.936+919G>A(IVS4+919G>A)的发病率很高。
Hum Mutat. 2009 Oct;30(10):1397-405. doi: 10.1002/humu.21074.